Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Rate and rhythm therapy in patients with atrial fibrillation and the risk of pacing and bradyarrhythmia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Incidence of atrial fibrillation in conjunction with breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Brugada syndrome: Let's talk about sex

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Fever-related arrhythmic events in the multicenter Survey on Arrhythmic Events in Brugada Syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Association between Type D personality and outcomes in patients with non-ischemic heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Polygenic predisposition to breast cancer and the risk of coronary artery disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cardiovascular Manifestations of Systemic Sclerosis: A Danish Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Utility of left atrial strain for predicting atrial fibrillation following ischemic stroke

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: Management of atrial fibrillation (AF) with rate and rhythm therapy can cause bradyarrhythmia. Objectives: To assess overall risk, temporal risk, and subgroup at risk of bradyarrhythmia-related events by rate and/or rhythm therapy drugs. Methods: Using Danish nationwide registries, patients with AF between 2000 and 2014 were included if prescribed with rate-lowering drugs (RLDs) or antiarrhythmic drugs (AADs). An adjusted time-dependent Poisson regression model estimated the association between RLDs and AADs with a composite endpoint of pacemaker, temporary pacing, and bradyarrhythmia hospitalization. Secondary outcomes were each individual event. Results: Among 135,017 AF patients, 9196 (6.8%) patients experienced the composite endpoint with a median follow-up of 3.7 (interquartile range [IQR]: 1.6–7.0) years. Median age was 74 (IQR: 65–82) years and 47.6% were women. With rate-lowering monotherapy as the reference, the incidence rate ratios (IRR) (95% confidence interval) for the composite endpoint were 1.36 (1.29–1.43) for rate-lowering dual therapy, 1.62 (1.43–1.84) for antiarrhythmic monotherapy, and 2.49 (2.29–2.71) for AAD combined with RLDs. Similar trend was found for each secondary outcome. Particularly amiodarone increased the risk. This association was strongest within the first 2 weeks of treatment. In those treated with AAD combined with RLDs, high-risk populations were patients ≥70 years (IRR: 3.35 [2.51–4.45] compared to patients <60 years), and women (IRR: 1.35 [1.15–1.57], compared to men). Conclusions: In real-world AF patients, rate-lowering dual therapy, antiarrhythmic monotherapy, and AADs combined with RLDs were positively associated with bradyarrhythmia-related events. The risk was highest in those treated with amiodarone, in the initial 2 weeks of treatment, in women, and in the elderly.

OriginalsprogEngelsk
TidsskriftHeart Rhythm
Vol/bind16
Udgave nummer9
Sider (fra-til)1348-1356
Antal sider9
ISSN1547-5271
DOI
StatusUdgivet - 1 sep. 2019

Bibliografisk note

Copyright © 2019 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

ID: 58042557